Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Influence of educational level on test and treatment for incident hypothyroidism

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Maternal thyroid disease and adiposity in mother and child

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effect of Anabolic-Androgenic Steroid Abuse on the Contact Activation System

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mineralocorticoid receptor antagonist improves cardiac structure in Type 2 Diabetes: Data from the MIRAD Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.

OBJECTIVE: To investigate N-terminal pro-BNP (NT-proBNP) in patients with GH disturbances before and after treatment, and in healthy gender- and age-matched controls.

SUBJECTS AND METHODS: Ten acromegalic patients (age 48 +/- 12 years) and 10 patients with GHD (age 41 +/- 14 years) were studied. None had symptoms or signs of cardiovascular disease except for hypertension. Serum NT-proBNP was measured before and 3, 6, 12 and 24 months after treatment.

RESULTS: Baseline NT-proBNP was lower in acromegalic patients [median (interquartile range) 24.3 (17.8-33.0) pg/ml] than in 20 healthy matched controls [57.9 (35.4-92.2) pg/ml; P < 0.001]. NT-proBNP increased during treatment (P = 0.002), concomitant with a decrease in IGF-I (P < 0.001). After 3 months of treatment NT-proBNP peaked, with a fourfold increase to 96.4 (57.8-113.2) pg/ml. NT-proBNP did not differ in patients with GHD compared with controls (P = 0.19), and did not change during treatment (P = 0.39).

CONCLUSION: Untreated patients with acromegaly had low NT-proBNP levels that increased fourfold after treatment. This is in contrast to other conditions with cardiac hypertrophy. Further studies are required to determine the significance of this novel finding in relation to acromegalic cardiac disease.

OriginalsprogEngelsk
TidsskriftClinical Endocrinology
Vol/bind66
Udgave nummer5
Sider (fra-til)619-25
Antal sider7
ISSN0300-0664
DOI
StatusUdgivet - maj 2007

ID: 52683671